ExeVir doses first patients with llama-derived anti-Covid antibody

A little over five months after pulling in a $50 million Series A, ExeVir is ready to take the next step with its llama-derived Covid-19 antibodies.

The Belgium-based biotech is officially launching a Phase I study in healthy volunteers for the llama antibody program, known as XVR011, announcing the dosing of its first patients Wednesday morning.